Vascotube GmbH has been acquired by Cirtec Medical Systems, LLC
November 2017 — Ordito GmbH, a private investment company, has sold Vascotube GmbH, a leading German manufacturer of high quality nitinol tubing, to 3i-backed Cirtec Medical Systems, LLC (Cirtec), a provider of design and contract manufacturing services for implantable and minimally invasive surgical devices. Financial details will remain confidential.
Founded in 2004, Vascotube processes nitinol tubing used in minimally invasive implantable medical devices. Nitinol’s properties of superelasticity and unique shape memory capabilities make it an ideal material for use in scaffold-like medical devices, such as peripheral and vascular stents, replacement heart valves, and embolic protection filters, that are compressed, inserted into the body intravenously and then expanded to pre-set shapes. Vascotube’s proprietary manufacturing process and focus on quality has made it a leading provider in its target markets and with its customers.
For over 25 years, Cirtec has been providing design, development, manufacturing and product transfer services for the medical device industry. With facilities in Los Gatos, California, Enfield, Connecticut, and Brooklyn Park, Minneapolis, the company specializes in outsourced solutions for active implantable devices in the areas of neuromodulation, drug delivery, cardiac rhythm management, ventricular assist, and minimally invasive devices.
Our role in the transaction
Oaklins’ teams in Germany and the USA acted as the exclusive M&A advisor to the seller in this cross-border transaction. The team had previously closed deals in the industry and was able to use its broad experience and contacts gained during the prior projects. Oaklins' team in Switzerland supported the transaction in its early stages.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreComtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more